Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05525455 Terminated - Cancer Clinical Trials

TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Start date: August 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.

NCT ID: NCT05388435 Terminated - Clinical trials for Advanced Solid Tumor

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Start date: September 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969 Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor activity of SKL27969

NCT ID: NCT05363605 Terminated - Breast Cancer Clinical Trials

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Start date: April 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.

NCT ID: NCT05271279 Terminated - Clinical trials for Advanced Solid Tumor

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Start date: December 24, 2021
Phase: Early Phase 1
Study type: Interventional

This is a prospective, multi-center, open-label, single-arm, investigator-initiated clinical trial to evaluate the safety and efficacy of oncolytic virus injection (OVV-01) in combination with trained immunity NK (tiNK) cell injection (IBR900) for patients with advanced malignant tumors.

NCT ID: NCT05255484 Terminated - Clinical trials for Advanced Solid Tumor

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Start date: May 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

NCT ID: NCT05188664 Terminated - Clinical trials for Advanced Solid Tumor

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: May 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

NCT ID: NCT05148533 Terminated - Clinical trials for Advanced Solid Tumor

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Start date: December 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to comfirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safty, effectiveness, PK, PD and biomarker properties for effective subjects.

NCT ID: NCT05148195 Terminated - Clinical trials for Advanced Solid Tumor

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Start date: December 22, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-cohort, multicenter Phase II study, the purpose of this study is to assess the efficacy and safety of envofolimab in combination with BD0801 injection with/without chemotherapy for the treatment of advanced solid tumors

NCT ID: NCT05144334 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of BTX-1188 in Subjects With Advanced Malignancies

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally administered in subjects with advanced malignancies.

NCT ID: NCT05099549 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Start date: November 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.